Last reviewed · How we verify
toludesvenlafaxine hydrochloride sustained-release tablets
toludesvenlafaxine hydrochloride sustained-release tablets is a Serotonin-norepinephrine reuptake inhibitor (SNRI) Small molecule drug developed by Shanghai Mental Health Center. It is currently FDA-approved for Major depressive disorder, Generalized anxiety disorder.
Toludesvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake at the presynaptic membrane.
Toludesvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake at the presynaptic membrane. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | toludesvenlafaxine hydrochloride sustained-release tablets |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the reuptake of both serotonin and norepinephrine, toludesvenlafaxine enhances monoaminergic neurotransmission in the central nervous system. The sustained-release formulation provides prolonged drug exposure, allowing for once-daily dosing. This mechanism is thought to restore neurochemical balance in mood disorders and anxiety conditions.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Dizziness
- Headache
- Insomnia
- Sexual dysfunction
- Sweating
Key clinical trials
- Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression (PHASE4)
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder (NA)
- To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets (PHASE4)
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder (NA)
- A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder. (PHASE3)
- Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- toludesvenlafaxine hydrochloride sustained-release tablets CI brief — competitive landscape report
- toludesvenlafaxine hydrochloride sustained-release tablets updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI
Frequently asked questions about toludesvenlafaxine hydrochloride sustained-release tablets
What is toludesvenlafaxine hydrochloride sustained-release tablets?
How does toludesvenlafaxine hydrochloride sustained-release tablets work?
What is toludesvenlafaxine hydrochloride sustained-release tablets used for?
Who makes toludesvenlafaxine hydrochloride sustained-release tablets?
What drug class is toludesvenlafaxine hydrochloride sustained-release tablets in?
What development phase is toludesvenlafaxine hydrochloride sustained-release tablets in?
What are the side effects of toludesvenlafaxine hydrochloride sustained-release tablets?
What does toludesvenlafaxine hydrochloride sustained-release tablets target?
Related
- Drug class: All Serotonin-norepinephrine reuptake inhibitor (SNRI) drugs
- Target: All drugs targeting Serotonin transporter (SERT) and norepinephrine transporter (NET)
- Manufacturer: Shanghai Mental Health Center — full pipeline
- Therapeutic area: All drugs in Psychiatry / Mental Health
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Compare: toludesvenlafaxine hydrochloride sustained-release tablets vs similar drugs
- Pricing: toludesvenlafaxine hydrochloride sustained-release tablets cost, discount & access